|
|
|
|
|
|
|
|
|
|
Experimental Information | |
Enzymatic Activity | |
Molecule Id | EGIN0001499 |
PMID | 20493747 |
Assay Used | MTT assay |
Experimently Validated | Yes |
EGFR (IC50) | - |
HER2 (IC50) | - |
HER4 (IC50) | - |
Mutant L858R (IC50) | - |
Mutant T790M (IC50) | - |
Double Mutant (IC50) | - |
Average ERBB2 and ERBB1 (IC50) | - |
Inhibition EGFR (%) | - |
Inhibitory Concentration | - |
Inhibition HER2 (%) | - |
Inhibitory Concentration | - |
Ki (EGFR) | - |
Ki (HER2) | - |
Ki (HER4) | - |
Kd (EGFR) | - |
Kd (L858R) | - |
Kd (T790M) | - |
Kd (L858R/T790M) | - |
Kd (Other mutation) | - |
Note | The paper describes the synthesis, anticancer activity and docking of some substituted benzothiazoles as tyrosine kinase inhibitors |
Extra | - |
Cellular Activity | ||||||||||||||
S.No. | Cell Line | Desp. | IC50 | IC80 | ED50 | GI50 | GI90 | EC50 | Kd | Inhibition (%) | Inhibitory Conc. | |||
1 | HGF-7 | - | - | - | - | - | - | - | - | 49.60% | 12.5 µM | |||
2 | HGF-7 | - | - | - | - | - | - | - | - | 12.68% | 25 µM | |||
3 | HGF-7 | - | - | - | - | - | - | - | - | 21.56% | 50 µM | |||
4 | HGF-7 | - | - | - | - | - | - | - | - | 37.08% | 100 µM | |||
Activity against Receptor | |
EGFR | Yes |
HER2 | - |
HER4 | - |
Wild type | Yes |
Mutant | - |
Inhibitor Binding | |
EGFR | - |
HER2 | - |
HER4 | - |